{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T16:22:10Z","timestamp":1761841330220},"reference-count":43,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2004,8,1]],"date-time":"2004-08-01T00:00:00Z","timestamp":1091318400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2004,8]]},"DOI":"10.1016\/j.ophtha.2003.11.013","type":"journal-article","created":{"date-parts":[[2004,8,5]],"date-time":"2004-08-05T07:00:10Z","timestamp":1091689210000},"page":"1480-1488","source":"Crossref","is-referenced-by-count":21,"title":["Low incidence of iris pigmentation and eyelash changes in 2 randomized clinical trials with unoprostone isopropyl 0.15%"],"prefix":"10.1016","volume":"111","author":[{"given":"Bernard E","family":"McCarey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry M","family":"Kapik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frances E","family":"Kane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2003.11.013_BIB1","unstructured":"Physicians' Desk Reference for Ophthalmic Medicines 2002. 29th ed. Montvale, NJ: Medical Economics Co.; 2000:315\u20137"},{"key":"10.1016\/j.ophtha.2003.11.013_BIB2","unstructured":"Physicians' Desk Reference for Ophthalmic Medicines 2001. 30th ed. Montvale, NJ: Medical Economics Co.; 2001:221"},{"key":"10.1016\/j.ophtha.2003.11.013_BIB3","unstructured":"Physicians' Desk Reference for Ophthalmic Medicines 2001. 30th ed. Montvale, NJ: Medical Economics Co.; 2001:240"},{"key":"10.1016\/j.ophtha.2003.11.013_BIB4","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0014-2999(01)01486-8","article-title":"Bimatoprost and its free acid are prostaglandin FP receptor agonists","volume":"432","author":"Sharif","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.ophtha.2003.11.013_BIB5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1089\/108076803762718105","article-title":"Hydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitro","volume":"19","author":"Davies","year":"2003","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2003.11.013_BIB6","unstructured":"Physicians' Desk Reference for Ophthalmic Medicines 2002. 30th ed. Montvale, NJ: Medical Economics Co.; 2001:306"},{"key":"10.1016\/j.ophtha.2003.11.013_BIB7","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1089\/108076801753266811","article-title":"Studies on receptor binding and signal transduction pathways of unoprostone isopropyl","volume":"17","author":"Bhattacherjee","year":"2001","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2003.11.013_BIB8","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1089\/jop.1996.12.489","article-title":"Ocular hypotensive mechanism of topical isopropyl unoprostone, a novel prostaglandin metabolite-related drug, in rabbits","volume":"12","author":"Taniguchi","year":"1996","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2003.11.013_BIB9","first-page":"3827","article-title":"The mechanism of IOP lowering action of Rescula, a new therapeutic agent for glaucoma and ocular hypertension in various animals\u2014comparison with prostaglandin F2 alpha","volume":"28","author":"Yoshida","year":"1994","journal-title":"Kiso Rinsho (Clin Rep)"},{"key":"10.1016\/j.ophtha.2003.11.013_BIB10","first-page":"987","article-title":"Ocular hypotensive action of isopropyl unoprostone","volume":"15","author":"Yuguchi","year":"1998","journal-title":"J Eye (Atarashii Ganka)"},{"key":"10.1016\/j.ophtha.2003.11.013_BIB11","first-page":"3193","article-title":"Mechanisms of action of unoprostone on trabecular meshwork contractility","volume":"42","author":"Thieme","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"suppl","key":"10.1016\/j.ophtha.2003.11.013_BIB12","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1016\/S0039-6257(97)80019-7","article-title":"Prostaglandin-induced iridial pigmentation in primates","volume":"41","author":"Sel\u00e9n","year":"1997","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ophtha.2003.11.013_BIB13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0161-6420(00)00495-4","article-title":"A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension","volume":"108","author":"Susanna","year":"2001","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2003.11.013_BIB14","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0161-6420(96)30749-5","article-title":"Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma","volume":"103","author":"Camras","year":"1996","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2003.11.013_BIB15","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S0161-6420(95)30798-1","article-title":"Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol","volume":"102","author":"Alm","year":"1995","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2003.11.013_BIB16","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0161-6420(96)30750-1","article-title":"A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension","volume":"103","author":"Watson","year":"1996","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2003.11.013_BIB17","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0161-6420(99)90115-X","article-title":"A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma","volume":"106","author":"Mastropasqua","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2003.11.013_BIB18","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0002-9394(01)01177-1","article-title":"Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension","volume":"132","author":"Netland","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2003.11.013_BIB19","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/00061198-200110000-00010","article-title":"Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension","volume":"10","author":"Goldberg","year":"2001","journal-title":"J Glaucoma"},{"key":"10.1016\/j.ophtha.2003.11.013_BIB20","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0161-6420(01)00584-X","article-title":"Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP","volume":"108","author":"Brandt","year":"2001","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2003.11.013_BIB21","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1358\/dof.2001.026.05.621031","article-title":"Bimatoprost","volume":"26","author":"Sorbera","year":"2001","journal-title":"Drugs Future"},{"key":"10.1016\/j.ophtha.2003.11.013_BIB22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1034\/j.1600-0420.2000.078001071.x","article-title":"Latanoprost","volume":"78","author":"Alm","year":"2000","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.ophtha.2003.11.013_BIB23","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0161-6420(98)91372-0","article-title":"Latanoprost. Two years' experience of its use in the United Kingdom","volume":"105","author":"Watson","year":"1998","journal-title":"Ophthalmology"},{"issue":"suppl","key":"10.1016\/j.ophtha.2003.11.013_BIB24","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1016\/S0039-6257(97)80020-3","article-title":"The incidence and time-course of latanoprost-induced iridial pigmentation as a function of eye color","volume":"41","author":"Wistrand","year":"1997","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ophtha.2003.11.013_BIB25","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/archopht.1997.01100160376025","article-title":"Latanoprost and hyperpigmentation of eyelashes","volume":"115","author":"Wand","year":"1997","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2003.11.013_BIB26","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1001\/archopht.118.5.718","article-title":"Eyelash formation secondary to latanoprost treatment in a patient with alopecia","volume":"118","author":"Mansberger","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2003.11.013_BIB27","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0002-9394(14)70870-0","article-title":"Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost","volume":"124","author":"Johnstone","year":"1997","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2003.11.013_BIB28","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/00061198-199712000-00014","article-title":"Iris-color change developed after topical isopropyl unoprostone treatment","volume":"6","author":"Yamamoto","year":"1997","journal-title":"J Glaucoma"},{"key":"10.1016\/j.ophtha.2003.11.013_BIB29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0002-9394(01)01337-X","article-title":"A double-masked randomized comparison of the efficacy and safety of unoprostone with timolol and betaxolol in patients with primary open-angle glaucoma including pseudoexfoliation glaucoma or ocular hypertension. 6 month data","volume":"133","author":"Nordmann","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2003.11.013_BIB30","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/00061198-200002000-00016","article-title":"Latanoprost-induced iris color darkening","volume":"9","author":"Camras","year":"2000","journal-title":"J Glaucoma"},{"issue":"suppl","key":"10.1016\/j.ophtha.2003.11.013_BIB31","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/S0039-6257(97)80018-5","article-title":"The color of the human eye","volume":"41","author":"Imesch","year":"1997","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ophtha.2003.11.013_BIB32","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1006\/exer.1998.0518","article-title":"Characterization of melanins in human irides and cultured uveal melanocytes from eyes of different colors","volume":"67","author":"Prota","year":"1998","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ophtha.2003.11.013_BIB33","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/archopht.1996.01100130433014","article-title":"Melanocytes and iris color. Light microscopic findings","volume":"114","author":"Wilkerson","year":"1996","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2003.11.013_BIB34","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0074-7696(08)60383-6","article-title":"Genetics, development, and malignancy of melanocytes","volume":"146","author":"Bennett","year":"1993","journal-title":"Int Rev Cytol"},{"key":"10.1016\/j.ophtha.2003.11.013_BIB35","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/bjo.71.7.549","article-title":"Is there any difference in the photobiological properties of melanins isolated from human blue and brown eyes?","volume":"71","author":"Menon","year":"1987","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2003.11.013_BIB36","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1006\/exer.1998.0581","article-title":"Alpha-methyl-p-tyrosine inhibits latanoprost-induced melanogenesis in vitro","volume":"68","author":"Drago","year":"1999","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ophtha.2003.11.013_BIB37","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1006\/exer.1999.0819","article-title":"Effects of latanoprost on tyrosinase activity and mitotic index of cultured melanoma lines","volume":"70","author":"Dutkiewicz","year":"2000","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ophtha.2003.11.013_BIB38","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1006\/exer.1999.0760","article-title":"Effect of prostaglandins A(2), E(1), F(2 alpha) and latanoprost on cultured human iridal melanocytes","volume":"70","author":"Hu","year":"2000","journal-title":"Exp Eye Res"},{"key":"10.1016\/j.ophtha.2003.11.013_BIB39","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0021-5155(01)00324-0","article-title":"Effects of isopropyl unoprostone on melanogenesis in mouse epidermal melanocytes","volume":"453","author":"Kashiwagi","year":"2001","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.ophtha.2003.11.013_BIB40","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S0304-4165(97)00068-8","article-title":"Chemical characterization of pheomelanogenesis starting from dihydroxyphenylalanine or tyrosine and cysteine. Effects of tyrosinase and cysteine concentrations and reaction time","volume":"1336","author":"Ozeki","year":"1997","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ophtha.2003.11.013_BIB41","series-title":"Principles and Practice of Ophthalmology","first-page":"3496","article-title":"Disorders of the eyelashes and eyebrows","author":"Rubin","year":"2000"},{"key":"10.1016\/j.ophtha.2003.11.013_BIB42","series-title":"Physiology of the Human Eye and Visual System","first-page":"9","article-title":"Eyebrows and eyelids","author":"Records","year":"1979"},{"key":"10.1016\/j.ophtha.2003.11.013_BIB43","series-title":"Adler's Physiology of the Eye","year":"1970"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642004003124?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642004003124?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T04:31:14Z","timestamp":1549341074000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642004003124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,8]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2004,8]]}},"alternative-id":["S0161642004003124"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2003.11.013","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2004,8]]}}}